1). Liao S, Lin J, Dang MT, et al. Growth suppression of hamster flank organs by topical application of catechins, ali zarin, curcumin, and myristoleic acid. Arch Dermatol Res. 2001; 293:200–5.
2). Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991; 57:1–7.
3). Kim KH, Park HY, Nam JH, et al. The inhibitory effect of curcumin on the growth of human colon cancer cells (HT-29, WiDr) in vitro. Korean J Gastroenterol. 2005; 45:277–84.
4). Notarbartolo M, Poma P, Perri D, Dusonchet L, Cer-vello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett. 2005; 224:53–65.
5). Sun M, Yang Y, Li H, et al. The effect of curcumin on bladder cancer cell line EJ in vitro. Zhong Yao Cai. 2004; 27:848–50.
6). Zhang J, Qi H, Wu C. Research of anti-proliferation of curcumin on A549 human lung cancer cells and its mechanism. Zhong Yao Cai. 2004; 27:923–7.
7). Duvoix A, Morceau F, Schnekenburger M, et al. Cur-eumin-induced cell death in two leukemia cell lines: K562 and Jurkat. Ann N Y Acad Sci. 2003; 1010:389–92.
8). Han SS, Keum YS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol. 2002; 35:337–42.
9). Lin JK. Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin. Arch Pharm Res. 2004; 27:683–92.
Article
10). Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta. 1994; 1224:597–600.
Article
11). Lin JK, Pan MH, Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors. 2000; 13:153–8.
Article
12). Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994; 371:346–7.
13). Hansson MJ, Persson T, Friberg H, et al. Powerful cyclosporin inhibition of calcium-induced permeability transition in brain mitochondria. Brain Res. 2003; 960:99–111.
Article
14). Ghribi O, DeWitt DA, Forbes MS, Arad A, Herman MM, Savory J. Cyclosporin A inhibits Al-induced cytochrome c release from mitochondria in aged rabbits. J Alzheimers Dis. 2001; 3:387–91.
Article
15). Sporbert A, Domaing P, Leonhardt H, Cardoso MC. PCNA acts as a stationary loading platform for transiently interacting Okazaki fragment maturation proteins. Nucleic Acids Res. 2005; 33:3521–8.
Article
16). Andreu EJ, Lledo E, Poch E, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005; 65:3264–72.
Article
17). Kwon YK, Jun JM, Shin SW, Cho JW, Suh SI. Curcumin decreases cell proliferation rates through BTG2-mediated cyclin D1 down-regulation in U937 cells. Int J Oncol. 2005; 26:1597–603.
Article
18). Chen A, Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol. 2005; 288:G447–56.
19). Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003; 17:590–603.
Article